Holen Sie sich die Stockscreener-App
4.69
7.32%
0.32
Handel nachbörslich:
4.60
-0.09
-1.92%
Schlusskurs vom Vortag:
$4.37
Offen:
$4.35
24-Stunden-Volumen:
2.30M
Relative Volume:
2.18
Marktkapitalisierung:
$692.15M
Einnahmen:
$170.28M
Nettoeinkommen (Verlust:
$-225.25M
KGV:
-3.5263
EPS:
-1.33
Netto-Cashflow:
$-167.02M
1W Leistung:
-7.68%
1M Leistung:
-0.21%
6M Leistung:
+35.55%
1J Leistung:
+10.35%
1-Tages-Spanne:
$4.29
$4.70
1-Wochen-Bereich:
$4.27
$5.10
52-Wochen-Spanne:
$2.28
$6.70
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Vergleichen Sie ADPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ADPT | 4.69 | 692.15M | 170.28M | -225.25M | -167.02M | -1.33 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Adaptive Biotechnologies (FRA:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Adaptive Biotechnologies (NASDAQ:ADPT) Financial Survey - Defense World
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares - Investing.com India
Adaptive Biotechnologies Corp: Is ADPT Stock Worth Buying? - Stocks Register
William Blair Has Bullish Forecast for ADPT FY2024 Earnings - MarketBeat
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Decrease in Short Interest - MarketBeat
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know - Yahoo Finance
Rubric Capital Management LP's Strategic Acquisition in Adaptive Biotechnologies Corp - GuruFocus.com
Matrix Capital Management Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 12.7% Following Analyst Upgrade - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher After Analyst Upgrade - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $7.00 - MarketBeat
ADPT (Adaptive Biotechnologies) Cash From Other Investing A - GuruFocus.com
Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Earnings call: Adaptive Biotechnologies posts robust MRD revenue growth - Investing.com
ARK Investment Management LLC Buys 189,134 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highl - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highlights: Strong MRD Growth Amidst ... - Yahoo Finance
ADPT stock touches 52-week high at $5.81 amid biotech rally By Investing.com - Investing.com South Africa
ADPT stock touches 52-week high at $5.81 amid biotech rally - Investing.com Canada
Adaptive Biotechnologies earnings beat by $0.07, revenue topped estimates - Investing.com
Adaptive Biotechnologies : Q3 2024 Earnings Presentation - Marketscreener.com
Adaptive Biotechnologies: Q3 Earnings Snapshot - CT Insider
ADPTAdaptive Biotechnologies Corporation Latest Stock News & Market Updates - StockTitan
Adaptive Biotechnologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings: Revenue S - GuruFocus.com
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results - Yahoo Finance
Medicare expands coverage for MRD test in lymphoma - Investing.com
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma - Yahoo Finance
ADPT (Adaptive Biotechnologies) Total Stockholders Equity : $241.6 Mil (As of Jun. 2024) - GuruFocus.com
Earnings To Watch: Adaptive Biotechnologies Corp (ADPT) Reports Q3 2024 Result - GuruFocus.com
Sumitomo Mitsui Trust Group's Strategic Acquisition in Adaptive Biotechnologies - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition in Adaptive Biotechno - GuruFocus.com
November 2024's Top US Penny Stocks With Growth Potential - Yahoo Finance
ADPT (Adaptive Biotechnologies) Cyclically Adjusted Book pe - GuruFocus.com
Adaptive Biotechnologies (ADPT) Scheduled to Post Earnings on Thursday - MarketBeat
Cancer Immunotherapy Global Market 2024 To Reach $175.39Billion By 2028 At Rate Of 12.1% - EIN News
Cancer Immunotherapy Global Market 2024 To Reach $175.39 Billion By 2028 At Rate Of 12.1% - EIN News
ADPT (Adaptive Biotechnologies) PE Ratio : At Loss (As of Oct. 30, 2024) - GuruFocus.com
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Receives $7.00 Consensus Price Target from Analysts - MarketBeat
Perhaps timely catching Adaptive Biotechnologies Corp (ADPT) would be a good idea - SETE News
Adaptive Biotechnologies Corp [ADPT] Stock sold by Insider Taylor Stacy L for $0.12 million - Knox Daily
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap UpStill a Buy? - MarketBeat
Stock Surge: Adaptive Biotechnologies Corp (ADPT) Closes at 4.94, Marking a 0.61 Increase/Decrease - The Dwinnex
Should investors be concerned about Adaptive Biotechnologies Corp (ADPT)? - US Post News
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap DownTime to Sell? - MarketBeat
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):